Glaucocalyxin A sensitizes ovarian cancer cells to PARP inhibitors by inducing DNA damage
Background Poly (ADP-ribose) polymerase inhibitors (PARPi) have demonstrated therapeutic advantages in ovarian cancer (OC) patients with homologous recombination (HR) deficiency. However, their effectiveness is limited in HR-proficient or acquired resistance tumors. Glaucocalyxin A (GLA) is an ent-kauranoid diterpene w...